Ipravent contains Ipratropium bromide as the active ingredient which belongs to a group of medicines known as anticholinergic bronchodilators. Anticholinergic bronchodilators work by relaxing the bronchial tubes (air passages) that carry air in and out of your lungs. This makes breathing less difficult.
Ipravent is used to relieve the symptoms of lung disease such as asthma or chronic obstructive bronchitis. It may be used in other conditions where breathing is difficult, such as after surgery or during assisted ventilation.
Ipravent is indicated for the treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD).
Ipravent is indicated, when used concomitantly with inhaled beta2-agonists, for treatment of reversible airways obstruction as in acute and chronic asthma.
Direction to Use
This medicinal product is for inhalation use only.
The dosage should be adapted to the individual needs of the patient. In children aged 12 years and under, only Ipravent Nebuliser Solution 1 ml should be used. The following doses are recommended:
Adults (including the elderly) and children over 12 years of age: 250 – 500 micrograms (i.e. one vial of 250 micrograms in 1 ml or one vial of 500 micrograms in 2ml) 3 to 4 times daily. The exact starting dose may vary depending on local guidelines.
For treatment of acute bronchospasm, 500 micrograms.
Repeated doses can be administered until the patient is stable. The time interval between the doses may be determined by the physician.
It is advisable not to exceed the recommended daily dose during either acute or maintenance treatment. Daily doses exceeding 2 mg in adults and children over 12 years of age should only be given under medical supervision.
Children 6 – 12 years of age: 250 micrograms (i.e. one vial of 250 micrograms in 1ml) up to a total daily dose of 1mg (4 vials).
The time interval between doses may be determined by the physician.
If therapy does not produce a significant improvement or if the patient’s condition gets worse, medical advice must be sought. In the case of acute or rapidly worsening dyspnoea (difficulty in breathing) a doctor should be consulted immediately.
Ipravent may be combined with a short-acting beta2-agonist in the same nebuliser chamber, for simultaneous administration where co-administration is required, in line with local prescribing guidelines. The solution should be used as soon as possible after mixing and any unused solution should be discarded.
Ipravent can be administered using a range of commercially available nebulising devices. The dose of nebuliser solution may need to be diluted according to local prescribing guidelines and in order to obtain a final volume suitable for the particular nebuliser being used (usually 2 – 4 ml); if dilution is necessary use only sterile sodium chloride 0.9% solution.
Common Side Effects of Ipravent are Breathlessness, Dryness in mouth, Cough, Bitter taste